feedburner

Enter your email address:

Delivered by FeedBurner

Lupin inks distribution pact with 3 firms to commercialise NaMuscla in Europe

Exeltis Healthcare SL, Cresco Pharma BV and Macure Pharma ApS will
commercialise NaMuscla for the symptomatic treatment of myotonia in
adults with non-dystrophic myotonic (NDM) disorders in certain
European Union (EU) territories, Lupin said in a statement.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-inks-distribution-pact-with-3-firms-to-commercialise-namuscla-in-europe/articleshow/76171829.cms



0 comments:

Post a Comment